Individuals with Down syndrome (DS) are at high risk for Alzheimer's disease (AD), yet accessible tools for routine clinical screening of AD in individuals with DS remain limited. Using data from the Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS), we show that integrating plasma pTau217 with performance on the m...
C. Vanderlip, S. Hartley, S. Krinsky-McHale et al.· Annals of Neurology· 0 citations
Findings support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention in appropriately selected at-risk individuals before the onset of clinical symptoms and support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention.
Yue-Xuan Xu, T. I. Gunasekaran, Yian Gu et al.· Lancet Neurology· 0 citations
Previous research has linked episodic memory to word learning and processing, but its role in broader lexical behaviors, such as lexical diversity, is still not well-understood. The present study leveraged existing data from a community-based sample of 564 adults (ages 27–89) who completed an episodic memory task a...
Phillip Hamrick, John Gunstad, Kate McClure et al.· The Mental Lexicon· 0 citations
A multi-dimensional attention framework that simultaneously captures both temporal dynamics and biomarker importance to predict disease progression across three fundamentally different populations could enable precision medicine approaches for data-limited cohorts across the Alzheimer's disease spectrum.
Zhi-Yuan Song, Si-Yang Song, Isabel C. H. Clare et al.· Research Square· 0 citations
An APOE-independent polygenic risk score for Alzheimer’s disease derived from multiancestry GWAS summary statistics shows consistent associations with cognitive, imaging, biomarker and neuropathological features in diverse populations.
N. Kurniansyah, S. Tasaki, H. Rehman et al.· Nature Genetics· 0 citations
An integrated research roadmap for MED is proposed that prioritizes biomarker-enriched cohorts, combination vascular and neurodegenerative therapies, and pragmatic trials, and offers the most plausible strategy to reduce the growing global burden of MED.
Adam de Havenon, Kevin N. Sheth, Carolyn A. Fredericks et al.· Neurotherapeutics· 0 citations
It is hypothesized that elevated neuroinflammation, indicated by reactive astrocytosis, acts on cerebrovascular disease and separately, on amyloid beta (Aβ) pathology, to promote downstream medial temporal lobe atrophy and memory impairment.
Batool M. Rizvi, P. Maillard, A. Posis et al.· Alzheimer's & Dementia· 0 citations
In a community-based sample, BD-p-tau217 emerged as the plasma biomarker most strongly associated with brain A{beta} deposition, although this association may be attenuated in the presence of moderate/severe kidney dysfunction or kidney failure.
Muge Akinci, Froogh Aziz, D. Guzman et al.· medRxiv· 0 citations
A double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use, and positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads).
G. Blazhenets, D. Soleimani-Meigooni, Konstantinos Chiotis et al.· Journal of the American Medi...· 5 citations
Higher plasma YKL‐40 was associated with greater white matter hyperintensity (WMH), whereas higher plasma GFAP was related to increased 18F‐florbetapir (FBP) standardized uptake value ratio (SUVR) and higher plasma p‐tau217 was associated with reduced MTL cortical thickness and hippocampal volume.
Batool Rizvi, Jenna N. Adams, Alison R. Bamford et al.· Alzheimer's & Dementia· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
